Article
Oncology
Chiara Valentini, Nadja Ebert, Lydia Koi, Manuel Pfeifer, Steffen Loeck, Christoph Erdmann, Mechthild Krause, Michael Baumann
Summary: This study aimed to compare the efficacy of fractionated radiotherapy versus radiochemotherapy with cisplatin in HPV-positive and negative human head and neck squamous cell carcinoma xenografts. The results showed that RCT significantly increased local tumor control in two out of three HPV-positive tumor models and one HPV-negative tumor model. In the pooled group of all HPV-positive tumors, RCT substantially enhanced local tumor control, while this effect was not observed in HPV-negative tumors.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Cell Biology
Yingchun Zhou, Junbin Zhang, Jinglin Gong, Xi Tang, Chengyao Zhang
Summary: This study investigated the role of UBE2C in radiotherapy resistance in HNSCC. The results showed that high expression of UBE2C was associated with poor prognosis in HNSCC patients. UBE2C was found to downregulate oxidative-stress-relative apoptosis induced by radiation and promote the development of malignant tumor cells.
Review
Oncology
Morena Fasano, Ida D'Onofrio, Maria Paola Belfiore, Antonio Angrisani, Valentina Caliendo, Carminia Maria Della Corte, Mario Pirozzi, Sergio Facchini, Marianna Caterino, Cesare Guida, Valerio Nardone, Alfonso Reginelli, Salvatore Cappabianca
Summary: This review discusses the role of clinical management, geriatric evaluation, and therapeutic approaches in elderly patients with head and neck squamous cell carcinoma (HNSCC). Elderly HNSCC patients are often frail with multiple comorbidities and may receive suboptimal treatment. The review summarizes different strategies for the clinical management of elderly HNSCC patients.
Article
Oncology
Christine H. Chung, Marcelo Bonomi, Conor E. Steuer, Jiannong Li, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Feifei Song, Juan C. Hernandez-Prera, Bruce M. Wenig, Helen Molina, Joaquim M. Farinhas, Caitlin P. McMullen, J. Trad Wadsworth, Krupal B. Patel, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Nabil F. Saba
Summary: The combination of cetuximab and nivolumab was well tolerated in patients with incurable head and neck squamous cell carcinoma. While patients without prior immune checkpoint inhibitor exposure showed a trend for more favorable progression-free survival, the improvement in 1-year overall survival did not reach statistical significance in this heavily treated patient population. Optimal sequencing of cetuximab and checkpoint inhibitors may impact prognosis and requires further evaluation.
Article
Cell Biology
Huan Li, Jun Wang, Lei He, Fengrui Zhang, Qingzhe Meng, Junhong Huang, Yahui Li, Rong Liu, Xinjie Yang, Jianhua Wei
Summary: A new scoring system based on EMT and hypoxia, named CIEH, has been developed for predicting prognosis and guiding treatment planning in HNSCC patients. The CIEH model, containing 14 characteristic factors, shows potential as biomarkers for HNSCC and is correlated with tumor immune infiltration.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Jing Li, Tao Yang, Qihong Wang, Yuedan Li, Haiyan Wu, Mei Zhang, Hong Qi, Hongxin Zhang, Jinfeng Li
Summary: This study demonstrates that SQLE plays a vital role in the progression of head and neck squamous cell carcinoma (HNSCC). High expression of SQLE is associated with aggressive tumor features and poor prognosis. Additionally, overexpression of SQLE enhances the proliferation, migration, and invasion abilities of HNSCC cells. The PI3K/Akt signaling pathway is implicated in the SQLE-mediated progression of HNSCC.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Eddy S. Yang, Eric Deutsch, Altan Mehmet, Jerome Fayette, Yungan Tao, Lisle Nabell, Sharon A. Spencer, Xuejing A. Wang, Elizabeth A. Spoljoric, Wei Zhang, Scott M. Hynes, Rodney L. Decker, Aimee K. Bence Lin, William N. William
Summary: This study aimed to investigate the feasibility of combining prexasertib with cisplatin-radiotherapy or cetuximab-radiotherapy in treating HNSCC, and concluded that prexasertib could be safely combined with cetuximab-radiotherapy, although a safe dose for cisplatin-radiotherapy was not established.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Nadege Kindt, Fabrice Journe, Stephane Carlier, Anne Trelcat, Alessandro Scalia, Sven Saussez
Summary: The study suggests that oxLDL may decrease the migration of HNC cell lines by regulating the CD36/beta-catenin pathway.
Article
Genetics & Heredity
Xiaobo Cui, Yali Zhang, Le Zhang, Jiayi Liu, Yunfei Bai, Yanru Cui, Boqian Wang, Shu Zhang, Xin Li
Summary: In this study, researchers found that Lon Peptidase 2, Peroxisomal (LONP2) was upregulated in head and neck squamous cell carcinoma (HNSCC) and its overexpression promoted cell growth and migration. Silencing of LONP2 inhibited tumor growth and improved apoptosis rate in HNSCC cells. Knockdown of LONP2 also downregulated the expression of plastin 3 (PLS3) and inhibited cell proliferation induced by LONP2 overexpression, suggesting that LONP2 exerts its oncogenic effect in HNSCC cells by positively regulating PLS3 expression.
Article
Oncology
Aditya Juloori, Rohan R. Katipally, Jeffrey M. Lemons, Anurag K. Singh, Renuka Iyer, Jared R. Robbins, Ben George, William A. Hall, Sean P. Pitroda, Fauzia Arif, John Fung, Anjana Pillai, Chih-Yi Liao, Manish Sharma, Stanley L. Liauw
Summary: This study investigated the safety and efficacy of stereotactic body radiation therapy (SBRT) with immunotherapy in patients with hepatocellular carcinoma (HCC). The results showed that the combination of SBRT with nivolumab plus ipilimumab had better survival and efficacy compared to immunotherapy alone in HCC patients, suggesting the need for further investigation.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Sara Varatanovic, Stefan Stoiber, Markus Haas, Alexander Lein, Lorenz Kadletz-Wanke, Faris F. Brkic
Summary: MK0752 shows potential as a therapeutic agent for HPV-positive HNSCC by exhibiting antineoplastic effects and inducing apoptosis. Further investigation is needed to validate these findings and understand the underlying mechanisms.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Sharon Changshan Wu, Karl Munger
Summary: Cancer/testis antigens show potential as therapeutic targets and prognostic biomarkers in head and neck squamous cell carcinoma, warranting further study to elucidate their role in the pathogenesis of these cancers. Their differential expression in HPV-positive HNSCC may mechanistically contribute to the genesis and clinical characteristics of these cancers, making them attractive targets for immunotherapies. These antigens, historically linked to diverse cancers, are increasingly implicated in various hallmarks of cancer, suggesting potential as cancer drivers.
Review
Biochemistry & Molecular Biology
Ching-Yun Hsieh, Ching-Chan Lin, Wei-Chao Chang
Summary: Taxanes, especially docetaxel, are widely used in combination therapy for head and neck squamous cell carcinoma (HNSCC) and have shown advantages in improving patient outcomes. Taxanes not only function as antimitotics, but also impair various oncogenic signaling pathways. However, the development of drug resistance remains a major obstacle to treatment response.
Article
Oncology
Kirsty Taylor, Jinfeng Zou, Marcos Magalhaes, Marc Oliva, Anna Spreafico, Aaron R. Hansen, Simon S. McDade, Vicky M. Coyle, Mark Lawler, Elena Elimova, Scott V. Bratman, Lillian L. Siu
Summary: Immune checkpoint blockade is an important treatment for recurrent/metastatic head and neck squamous cell cancer, but only a subset of patients benefit from it. Monitoring plasma circulating tumor DNA (ctDNA) levels and changes during treatment can help assess disease burden and predict patient outcomes. This study showed that early changes in ctDNA after one cycle of treatment can predict progression-free survival and overall survival in patients with recurrent/metastatic head and neck squamous cell cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Sebastian Wimmer, Lisa Deloch, Michael Hader, Anja Derer, Fridolin Grottker, Thomas Weissmann, Markus Hecht, Antoniu-Oreste Gostian, Rainer Fietkau, Benjamin Frey, Udo S. Gaipl
Summary: Following radiotherapy, the HPV status may not distinctly predict immunological responses, highlighting the importance of individualized ICM expression in selecting patients for targeted immune therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
